ImmunityBio Partners With Accord Healthcare To Provide Access To ANKTIVA In Combination With BCG For Eligible Patients In EU With BCG-Unresponsive NMIBC CIS

• ImmunityBio partner Accord Healthcare to deploy an 85-person sales force to drive ANKTIVA commercialization across 30 countries
• Dublin-based subsidiary to support ImmunityBio's distribution and commercialization strategy in Europe
• Distribution partnership supports ImmunityBio's mission to expand global access to ANKTIVA
• Approximately 157,000 people are diagnosed annually with non-muscle invasive bladder cancer (NMIBC) in the EU and UK, with an estimated 10% to 20% presenting with NMIBC carcinoma in situ, with or without papillary tumors1, 2
• Bladder cancer indication expansion update: response submitted to U.S. FDA for BCG-unresponsive papillary-only disease; randomized BCG naïve trial nearing full enrollment

ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced a partnership with Accord Healthcare to provide access to ANKTIVA® (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Guérin (BCG) for eligible patients in the European Union with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS), with or without papillary disease. ImmunityBio also announced the establishment of an Irish subsidiary in Dublin to support the company's distribution and commercialization strategy throughout Europe.